No significant evidence for protection against cardiovascular outcomes with metformin in heart failure

Metformin did not significantly affect the risk of cardiovascular outcomes in patients with heart failure with reduced ejection fraction and diabetes or at risk of diabetes. These were the main findings of the Met-HeFT trial and a meta-analysis presented in a Hot Line session at ESC Congress 2026.

≈